True Vision MN LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

True Vision MN LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,048 shares of the company's stock, valued at approximately $267,000.

Several other hedge funds have also made changes to their positions in the business. US Bancorp DE increased its holdings in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after purchasing an additional 1,508 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth approximately $67,000. Charles Schwab Investment Management Inc. raised its holdings in Hims & Hers Health by 7.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company's stock valued at $43,448,000 after acquiring an additional 129,416 shares in the last quarter. Finally, Keybank National Association OH purchased a new position in Hims & Hers Health in the fourth quarter worth approximately $237,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HIMS. Bank of America boosted their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their target price for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Piper Sandler reiterated a "neutral" rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $39.58.

Hims & Hers Health Trading Down 4.7%

Shares of NYSE HIMS traded down $2.36 during midday trading on Friday, reaching $47.91. 18,925,676 shares of the company were exchanged, compared to its average volume of 23,898,503. The stock has a market cap of $10.72 billion, a P/E ratio of 69.44, a PEG ratio of 1.76 and a beta of 2.02. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The stock has a fifty day simple moving average of $53.68 and a 200 day simple moving average of $41.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm's revenue for the quarter was up 110.7% on a year-over-year basis. During the same period last year, the firm earned $0.05 EPS. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Michael Chi sold 17,102 shares of the firm's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the sale, the insider owned 278,654 shares in the company, valued at $16,649,576.50. This trade represents a 5.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Irene Becklund sold 8,485 shares of the business's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total value of $506,978.75. Following the transaction, the insider owned 712 shares in the company, valued at $42,542. The trade was a 92.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 670,250 shares of company stock valued at $34,487,591. Corporate insiders own 17.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.